Reperfusion therapies, including intravenous thrombolysis and endovascular thrombectomy, have been recommended as the most effective strategy for acute ischemic stroke (AIS) by current guidelines.
1 In 2012, an estimated 37% of patients had a good prognosis through intravenous thrombolysis,
2 and a 2016 meta-analysis estimated that about 46% of patients with large artery occlusion had a good outcome after endovascular therapy.
3 Nevertheless, only a small proportion of the population can be treated with reperfusion therapies due to the limited therapeutic window and technical requirements. An active area of research has been to find new neuroprotective strategies to reduce the disability of AIS.
4,5